European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Pathirana, D
European S3-guidelines on the systemic treatment of psoriasis vulgaris. [electronic resource] - Journal of the European Academy of Dermatology and Venereology : JEADV Oct 2009 - 1-70 p. digital
Publication Type: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
1468-3083
10.1111/j.1468-3083.2009.03389.x doi
Adalimumab
Alefacept
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Cyclosporine--adverse effects
Dermatologic Agents--adverse effects
Etanercept
Humans
Immunoglobulin G--adverse effects
Infliximab
Methotrexate--adverse effects
PUVA Therapy--adverse effects
Psoriasis--drug therapy
Receptors, Tumor Necrosis Factor--therapeutic use
Recombinant Fusion Proteins--adverse effects
Retinoids--adverse effects
European S3-guidelines on the systemic treatment of psoriasis vulgaris. [electronic resource] - Journal of the European Academy of Dermatology and Venereology : JEADV Oct 2009 - 1-70 p. digital
Publication Type: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
1468-3083
10.1111/j.1468-3083.2009.03389.x doi
Adalimumab
Alefacept
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Cyclosporine--adverse effects
Dermatologic Agents--adverse effects
Etanercept
Humans
Immunoglobulin G--adverse effects
Infliximab
Methotrexate--adverse effects
PUVA Therapy--adverse effects
Psoriasis--drug therapy
Receptors, Tumor Necrosis Factor--therapeutic use
Recombinant Fusion Proteins--adverse effects
Retinoids--adverse effects